Patients | Controls | p-value | |
Subjects n | 119 | 124 | |
Demographics and exposure history | |||
Age years | 47.3±2.7 | 45.7±3.0 | <0.001 |
Males | 61% | 52% | 0.162 |
Body mass index kg·m−2 | 26.5±6.9 | 26.1±4.6 | 0.650 |
Cumulative smoking exposure pack-years | 34.5±17.0 | 24.7±11.7 | <0.001 |
Current smokers | 38% | 23% | 0.014 |
Family history and early-life events | |||
Familiar asthma | 24% | 19% | 0.342 |
Familiar bronchitis | 34% | 15% | 0.001 |
Familiar emphysema | 29% | 8% | <0.001 |
Familiar hypertension | 49% | 48% | 1 |
Symptoms | |||
mMRC score ≥2 | 13% | 1% | 0.001 |
Previous treatments and use of healthcare resources | |||
Oral Corticosteroid use | 2% | 0% | 0.460 |
Number of exacerbations | 0.7± 0.9 | NA | |
Physiology | |||
FEV1/FVC (post-bd) % | 49.0± 11.8 | 80.1±4.9 | <0.001 |
FEV1 (post-bd) % ref. | 49.0± 18.2 | 103.9±10.8 | <0.001 |
FVC (post-bd) % ref. | 82.5± 22.1 | 112.8±12.6 | <0.001 |
Total lung capacity % ref. | 114.0± 17.5 | 102.79±11.4 | <0.001 |
6MWD test | |||
Distance walked m | 425.6±137.7 | NA | |
Imaging | |||
Presence of CT emphysema n (%) | 60% | 8% | <0.001 |
Biomarkers | |||
Basophils (%) | 0.33± 0.23 | 0.32± 0.24 | 0.527 |
Eosinophils (%) | 2.6± 2.1 | 2.55± 1.58 | 0.464 |
Haematocrit | 0.44±0.04 | 0.43± 0.04 | 0.009 |
Lymphocytes (%) | 28.04± 8.61 | 30.22± 7.11 | 0.024 |
Monocytes (%) | 5.96± 2.49 | 5.76± 2.23 | 0.682 |
Segmented neutrophils (%) | 63.06± 9.52 | 61.15± 8.29 | 0.102 |
Total neutrophils (total ANC) | 5.23± 2.2 | 4.71± 1.95 | 0.050 |
Total neutrophils (%) | 63.06± 9.52 | 61.15± 8.29 | 0.102 |
White blood cells ×109/L | 8.11± 2.49 | 7.56± 2.37 | 0.057 |
Results are presented as mean±sd or proportion. p-values <0.05 are highlighted in bold text. mMRC: modified Medical Research Council scale; post-bd: post-bronchodilator; % ref.: % of reference value; 6MWD: 6-min walk test; CT: computed tomography; ANC: total absolute neutrophil count.